Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Preferred Shares: 2023-2025

Historic Preferred Shares for Spyre Therapeutics (SYRE) over the last 2 years, with Sep 2025 value amounting to $146.4 million.

  • Spyre Therapeutics' Preferred Shares changed negligibly% to $146.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $146.4 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $146.4 million for FY2024, which is 20.82% down from last year.
  • Per Spyre Therapeutics' latest filing, its Preferred Shares stood at $146.4 million for Q3 2025, which was down 0.00% from $146.4 million recorded in Q2 2025.
  • Spyre Therapeutics' 5-year Preferred Shares high stood at $184.9 million for Q4 2023, and its period low was $146.4 million during Q2 2024.
  • Moreover, its 3-year median value for Preferred Shares was $146.4 million (2025), whereas its average is $156.1 million.
  • Data for Spyre Therapeutics' Preferred Shares shows a maximum YoY declined of 20.82% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows Spyre Therapeutics' Preferred Shares stood at $184.9 million in 2023, then dropped by 20.82% to $146.4 million in 2024, then remained steady at $146.4 million in 2025.
  • Its last three reported values are $146.4 million in Q3 2025, $146.4 million for Q2 2025, and $146.4 million during Q1 2025.